Data needs to move securely across the stack while remaining compliant and scalable
The FDA does note that during a drug shortage, compounded versions can be produced if they meet Federal Food, Drug and Cosmetic Act requirements, but urged caution
This approach is clinically defensible and reduces barriers to starting treatment, but it means that some patients may begin treatment without the metabolic baseline data that could improve their care
The atherosclerotic benefits provided by GLP-1RA, which reflect the improvement of glycated hemoglobin level, blood pressure, albumin-to-creatinine ratio and other favorable hemodynamic effects, may be responsible, at least in part, for this finding
Ultimately, 1 article was included in this narrative review